About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

WITHDRAWNNANCT04462133

Optimal Tailored Treatment for H. Pylori Infection

The efficacy of the current standard triple therapy is at an unacceptably low level. Resistance to antibiotics is suspected to be the major cause of the low efficacy of standard triple therapy. Point ...

Lead sponsor: Incheon St.Mary's Hospital•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Sponsors

Lead Sponsor

Incheon St.Mary's Hospital

Patients are randomly assigned to the empirical therapy group and tailored therapy group. The empirical therapy group recieves triple therapy of 7 or 14 days. The tailored therapy group receives treatment based on their DPO-PCR results. Patients who are sensitive to clarithromycin based on DPO-PCR receives triple therapy for 7 or 14 days. Patients who are resistant to clarithromycin based on DPO-PCR recieves bismuth quadruple therapy for 7 or 14 days.

Age

19 - 79 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•consecutive subjects who underwent upper gastrointestinal endoscopy and who had a confirmed diagnosis of H pylori infection

Exclusion Criteria

•subjects younger than 18 years old
•subjects with a history of H pylori eradication
•subjects who had previous gastric surgery
•subjects who were pregnant or lactating
•subjects with serious concurrent illness
•subjects who were administered antibiotics, bismuth, or PPIs in the 8 weeks preceding the study
•subjects with a history of allergy to any one of the compounds in this study

Related studies

RECRUITINGPhase 4

Vonoprazan-based Versus Esomeprazole-based Triple Therapy for Helicobacter Pylori Eradication

NCT07537634 · Helicobacter Pylori Infection, Dyspepsia, and more

Effect of PPIs on Stool DNA Test for H. Pylori

NCT07516262 · Helicobacter Pylori Infection

Registry for the Management of Helicobacter Pylori Infection in Shandong Province

NCT07335406 · HELICOBACTER PYLORI INFECTIONS

Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial

NCT07179159 · HELICOBACTER PYLORI INFECTIONS

RECRUITINGPhase 2

Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection

NCT07293910 · HELICOBACTER PYLORI INFECTIONS, Helicobacter Infection, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: May 16, 2024Terms

Trial snapshot

StatusWITHDRAWN

PhaseNA

Enrollment—

Start dateSep 2020

Last updatedMay 16, 2024

Condition

Helicobacter Pylori Infection Antibiotic Resistant Infection

Locations shown

Incheon St. Mary's Hospital

Incheon

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 16, 2024Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions